Objective-Brain expresses abundant lipocalin-type prostaglandin (PG) D 2 (PGD 2 ) synthase but the role of PGD 2 and its metabolite, 15-deoxy-⌬ 12,14 PGJ 2 (15d-PGJ 2 ) in brain protection is unclear. The aim of this study is to assess the effect of 15d-PGJ 2 on neuroprotection. Methods and Results-Adenoviral transfer of cyclooxygenase-1 (Adv-COX-1) was used to amplify the production of 15d-PGJ 2 in ischemic cortex in a rat focal infarction model. Cortical 15d-PGJ 2 in Adv-COX-1-treated rats was increased by 3-fold over control, which was correlated with reduced infarct volume and activated caspase 3, and increased peroxisome proliferator activated receptor-␥ (PPAR␥) and heme oxygenase-1 (HO-1). Intraventricular infusion of 15d-PGJ 2 resulted in reduction of infarct volume, which was abrogated by a PPAR␥ inhibitor. Rosiglitazone infusion had a similar effect. 15d-PGJ 2 and rosiglitazone at low concentrations suppressed H 2 O 2 -induced rat or human neuronal apoptosis and necrosis and induced PPAR␥ and HO-1 expression. The anti-apoptotic effect was abrogated by PPAR␥ inhibition. Conclusion-15d-PGJ 2 suppressed ischemic brain infarction and neuronal apoptosis and necrosis in a PPAR␥ dependent manner. 15d-PGJ 2 may play a role in controlling acute brain damage induced by ischemia-reperfusion. (Arterioscler Thromb Vasc Biol. 2006;26:481-487.)
P rostaglandin (PG) H synthase-1 (also known as cyclooxygenase-1 [COX-1]) is constitutively expressed in almost all mammalian cells. 1 It is a bifunctional enzyme with a cyclooxygenase activity that converts arachidonic acid to PG G 2 (PGG 2 ) and a peroxidase activity that converts PGG 2 to PGH 2 . 2 PGH 2 is converted to diverse prostanoids by specific enzymes. COX-1 plays an important role in maintaining physiological homeostasis and protecting brain tissues from ischemia-reperfusion (I/R) injury. COX-1 deleted mice are highly susceptible to ischemic brain infarction, 3 whereas COX-1 overexpression protects brain from I/R damage, which is abrogated by a selective COX-1 inhibitor. 4 COX-1 overexpression in ischemic brain augments the production of PGI 2 , PGD 2 , and PGE 2 , and suppresses leukotriene B 4 (LTB 4 ) and LTC 4 . As LTB 4 and LTC 4 have been shown to be detrimental to brain tissue, whereas PGI 2 is protective, [5] [6] [7] COX-1 overexpression tilts the eicosanoid balance toward tissue protection. PGD 2 is elevated in COX-1 overexpressed brain tissues but its role in brain I/R injury is unclear. Brain is enriched in lipocalin-type PGD synthase (L-PGDS), which catalyzes the formation of abundant PGD 2 . 8 The role of PGD 2 in I/R brain injury is unclear. As 15-deoxy-⌬ 12, 14 ; PGJ 2 (15d-PGJ 2 ), a nonenzymatic product of PGD 2 , was shown to possess anti-inflammatory properties through activation of peroxisome proliferator activated receptor-␥ (PPAR␥), 9 -13 PGD 2 has been implicated in tissue protection. However, it has recently been argued that the tissue 15d-PGJ 2 level is too low to elicit an anti-inflammatory action in vivo, especially in vascular tissues. 14 In view of abundant expression of L-PGDS and PGD 2 in brain, we postulated that 15d-PGJ 2 contributes to cerebral protection. Our experimental findings show a considerable amount of 15d-PGJ 2 in ischemia brain, which was enhanced by adenoviral COX-1 gene transfer. 15d-PGJ 2 and rosiglitazone reduced brain infarct volume, inhibited brain and neuronal apoptosis, suppressed NF-B activation, and upregulated heme oxygenase-1 (HO-1) in a PPAR␥dependent manner.
Methods

Stroke Model
The rat focal cerebral infarction model has been described previously. 4 cerebral artery (MCA) was ligated reversibly with a 10-0 suture, and both common carotid arteries were occluded with aneurysm clips. At the indicated time point, the aneurysm clips and the suture were removed and blood flow in all 3 arteries was restored. The animals were kept in an air-ventilated incubator at 24.0Ϯ0.5°C for 24 hours and then euthanized under anesthesia. Brains were quickly removed and the ischemic or contralateral cerebral cortex was isolated and frozen. Infarct volume was measured by incubating coronally dissected brain slices with 2,3,5-triphenyltetrazolium chloride as previously described. 4 All procedures were performed in accordance with the Public Health Service Guide for the Care and Use of Laboratory Animals and approved by the Academia Sinica Animal Studies Committee.
Cell Culture and H 2 O 2 -Mediated Oxidative Stress
Rat primary cortical neuron cultures were prepared from 14-to 15-day-old fetus according to procedures previously described. 15, 16 All the experiments were performed on cultured neurons after 12 to 14 days in vitro. More than 90% of cells stained positive for microtubal associated protein-2. Human BE(2)-C neuroblastoma cells (American Type Culture Collection) were grown to 70% confluence in a 1:1 mixture of DMEM and Ham's F-12K medium in a humidified 5% CO 2 atmosphere. H 2 O 2 , 15d-PGJ 2 (Cayman), bisphenol A diglyceryl ether (BADGE) (Fluka), rosiglitazone (Cayman), zVADfmk, and zDEVDfmk (Biovision) were added to serumdeprived BE(2)-C cells either alone or in various combinations for 12 hours. Extent of cytotoxicity was assessed by lactate dehydrogenase (LDH) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assays according to manufacturer's instructions (Roche).
Preparation of Replication-Defective Recombinant Adenoviral Vectors
Viral vectors were prepared as previously described. 17 We constructed in the replication-defective recombinant adenoviral (rAd) vector a human phosphoglycerate kinase (PGK) promoter to drive COX-1 (Adv-COX-1), green fluorescent protein (Adv-GFP), or PGK alone to serve as the control (Adv-PGK).
Intracerebral Ventricular Infusion of Adenoviral Constructs and 15d-PGJ 2
The procedure was performed as previously described. 4 Briefly, anesthetized rats were placed in a stereotaxic apparatus; 10 L of artificial cerebrospinal fluid containing rAd at 10 8 plaque-forming units (pfu) or 10 L of 15d-PGJ 2 (1 to 50 pg) were infused into the right lateral ventricle at a rate of 5 L/min at the following coordinates: Anterior, 2.5 mm caudal to bregma; Right, 2.8 mm lateral to midline; and Ventral, 3.0 mm ventral to dural surface. Periodic confirmation of proper placement of the needle was performed with infusion of fast green. To delineate the distribution of the transgene expression, we infused Adv-GFP into the right lateral ventricle for 72 hours and GFP was visualized under microscopy. GFP was detected in the lining of ependymal cells and cells surrounding the right ventricle in all 8 coronal brain slices but not in the left ventricle ( Figure I , available online at http://atvb. ahajournals.org).
Measurements of Brain Tissue PGD 2 and 15d-PGJ 2
Brain tissues for PGD 2 and 15d-PGJ 2 analysis were prepared as previously described. 4 Briefly, the ischemic cortex was homogenized in 1 mL ice-cold buffer and centrifuged at 55 000g for 1 hour. Eicosanoids were extracted with a Sep-Pak C18 cartridge and analyzed by enzyme immunoassays using reagents from Cayman for PGD 2 and R&D Systems for 15d-PGJ 2 .
Western Blot Analysis
Analysis of proteins in the cortex and BE(2)-C cells by Western blotting was performed as described previously, 4 using antibodies for COX-1 (Cayman, 1:1000), COX-2 (Cayman, 1:1000), PPAR␥ (Santa Cruz, 1:500), HO-1 (ABR, 1:2000), GAPDH (BD Pharmingen, 1:10000), active caspase-3 (Cell signaling, 1:500), Poly (ADPribose) polymerase (PARP) (Cell signaling, 1:1000), and IB-␣ (Santa Cruz, 1;1000). Protein bands were visualized by an enhanced chemiluminescence system (Pierce).
Nuclear Extract Preparation and Electrophoretic Mobility Shift Assay
Nuclear extracts of brain were prepared and electrophoretic mobility shift assay (EMSA) was performed as previously described. 18 Cerebral cortex was gently homogenized and centrifuged at 3300g for 15 minutes. Nuclei pellets were resuspended and centrifuged at 25 000g for 30 minutes at 4°C and the supernatant was dialyzed; 20 g of nuclear extracts were incubated with 5 ng of a 32 P-labeled B-containing probe at room temperature for 30 minutes. The mixture was run on a 5% nondenaturing polyacrylamide gel. For supershift experiments, antibodies against p65 or p50 (Santa Cruz) were added before adding labeled probes. Gels were dried under vacuum and exposed to Kodak X-Omat/XB-1 films. The radioactive bands were quantified by densitometry.
Analysis of Apoptosis by Flow Cytometry
Cells were fixed in ice-cold 70% ethanol for 30 minutes at 4°C. After centrifugation, cells were resuspended and incubated in phosphatebuffered saline containing 1 mg/mL RNase A and 10 g/mL propidium iodide (PI) at room temperature for 30 minutes and analyzed in a fluorescence-activated-cell sorter (FACS) caliber flow cytometer (BD Bioscience). Percentages of cells with hypodiploid DNA (sub-G 0 /G 1 ) were measured.
Statistical Analysis
Analysis of variance (ANOVA) was used to compare the temporal expression of proteins, infarct volumes, and eicosanoid levels. The level of significance for differences between groups was further analyzed with post-hoc Fisher's protected t tests by GB-STAT 5.0.4 (Dynamic Microsystem, Inc, Silver Springs, Md). PϽ0.05 was considered significant.
Results
Adenoviral COX-1 Gene Transfer Increased 15d-PGJ 2 in Ischemic Brain
Adv-COX-1 infusion 72 hours before a 50-minute MCA occlusion resulted in increased COX-1 proteins, PGD 2 , and 15d-PGJ 2 levels accompanied by a reduction in infarct volume ( Figure 1a ). The extent of 15d-PGJ 2 increase (Ϸ3-fold) correlated with that of COX-1 increase (Ϸ3-fold) ( Figure 1b ). COX-2 was markedly suppressed whereas PPAR␥ and HO-1 were elevated by Adv-COX-1 treatment (Figure 1b ). EMSA analysis reveals increased p50/p65 NF-B DNA binding in ischemic cortex as previously reported, 19 which was abrogated by Adv-COX-1 ( Figure II , available online at http://atvb.ahajournals.org).
15d-PGJ 2 and Rosiglitazone Reduced Infarct Volume
To confirm the protective effect of 15d-PGJ 2 , we infused 15d-PGJ 2 24 hours before a 50-minute MCA occlusion. 15d-PGJ 2 at 1 pg reduced the infarct volume by Ͼ50% ( Figure III , available online at http://atvb.ahajournals.org). However, when 15d-PGJ 2 was infused immediately after the 50 minutes of ischemia, it failed to reduce infarct volume significantly even when the dose was increased to 50 pg ( Figure III) . 15d-PGJ 2 infusion immediately after ischemia reduced the infarct size in right cortex when the MCA occlusion was shortened to 30 minutes ( Figure IV , available online at http://atvb.ahajournals.org) in a concentrationdependent manner (Figure 2a ). It remained effective when administered 2 hours after ischemia but was no longer effective at 3 hours after ischemia (Figure 2a ). To determine whether the anti-infarct action of 15d-PGJ 2 is mediated via PPAR␥, we infused GW9662, a selective inhibitor of PPAR␥. GW9662 completely abrogated the protective effect of 15d-PGJ 2 (Figure 2b ). Infusion of rosiglitazone (50 ng) immediately after the 30-minute ischemia reduced the infarct volume by Ͼ80% and remained effective when infused 2 hours, but not 3 hours, after ischemia. 15d-PGJ 2 and rosiglitazone reduced IB␣ degradation to a similar extent ( Figure V , available online at http://atvb.ahajournals.org). These results suggest that 15d-PGJ 2 reduced infarct volume via a PPAR␥dependent pathway.
PPAR␥ Ligands Upregulated PPAR␥ Protein Levels
The PPAR␥ protein level in ischemic brain was higher than control (Figure 3a) , which was concentration-dependently enhanced by 15d-PGJ 2 (Figure 3a ), and rosiglitazone (data not shown). 15d-PGJ 2 upregulated PPAR␥ in normal brains in a time-dependent manner, with a 3-fold increase in the protein level 12 hours after infusion (Figure 3b ).
Adv-COX-1, 15d-PGJ 2 , and Rosiglitazone Inhibited Brain Tissue Caspase 3 Activation
To determine whether the tissue protective effects are mediated by blocking apoptosis, we measured activated caspase-3 in ischemic cortex treated with Adv-COX-1 or PPAR␥ ligands. Activated caspase-3 was increased in ischemic cortex, which was abrogated by Ad-COX-1, 15d-PGJ 2 (Figure 4a and 4b), or rosiglitazone infusion (data not shown). 15d-PGJ 2 at 50 pg or rosiglitazone at 50 ng reduced activated caspase-3 to the basal level and Adv-COX-1 suppressed caspase 3 activation to a similar extent.
15d-PGJ 2 Suppressed Neuronal Apoptosis and Necrosis
The in vivo data reveal that 15d-PGJ 2 protected brain tissues from I/R-induced cell death. To ascertain its effect on protecting neuronal survival, we evaluated the effect of 15d-PGJ 2 induced LDH release from rat and human neurons ( Figure  5a ), which was abrogated by BADGE, a PPAR␥ inhibitor ( Figure 5a ). Paradoxically, 15d-PGJ 2 at higher concentrations (Ͼ5 mol/L) induced LDH release from BE(2)-C cells (Figure 5b ). Similar to 15d-PGJ 2 , rosiglitazone at 0.5 mol/L suppressed LDH release by Ͼ50%, which was abrogated by BADGE ( Figure VIIa , available online at http://atvb. ahajournals.org), but paradoxically induced LDH release at higher concentrations (Ն10 mol/L) ( Figure VIIb) . Caspase inhibitors blocked H 2 O 2 -induced LDH release and restored the inhibitory action of 15d-PGJ 2 even in the presence of BADGE (Figure 5c ). To confirm that 15d-PGJ 2 protects neurons from H 2 O 2induced apoptosis, we measured apoptotic cells by flow cytometry. 15d-PGJ 2 inhibited H 2 O 2 -induced neuronal apoptosis by Ͼ50%, which was abrogated by BADGE ( Figure  6a ). Moreover, 15d-PGJ 2 inhibited H 2 O 2 -induced caspase 3 activation and PARP cleavage in BE(2)-C cells, which were also abrogated by BADGE (Figure 6b ). 15d-PGJ 2 increased PPAR␥ protein levels by Ϸ2-fold, which was not influenced by H 2 O 2 treatment (Figure VIIIa, available online at http://atvb.ahajournals.org). Because HO-1 is an important mediator of cell survival, we determined whether HO-1 level is altered by H 2 O 2 and 15d-PGJ 2 treatment. 15d-PGJ 2 increased HO-1 protein levels by Ϸ10fold ( Figure VIIIb) . H 2 O 2 did not alter HO-1 level, nor did it interfere with the stimulatory action of 15d-PGJ 2 ( Figure  VIIIb) . By contrast, the HO-1 stimulatory action of 15d-PGJ 2 was blocked by BADGE ( Figure VIIIb) .
Discussion
Results from this study indicate that a considerable quantity of 15d-PGJ 2 is generated in I/R-injured cortex, which is augmented by COX-1 overexpression. Elevation of 15d-PGJ 2 was correlated with a Ͼ50% reduction in infarct volume and a Ͼ80% reduction in activated caspase 3. 15d-PGJ 2 has a potent effect on controlling the expansion of the infarct size as administration of 15d-PGJ 2 intraventricularly at 1 pg was sufficient to induce Ϸ50% reduction in infarct volume. These results suggest that the endogenously generated 15d-PGJ 2 may be involved in suppressing I/R-induced infarct expan- sion. However, the causal relationship between the endogenous generation of 15d-PGJ 2 and reduction in infarct volume is not fully established in our study as we have not performed time-course experiments to demonstrate that 15d-PGJ 2 generation precedes the reduction in the infarct size. Work is in progress to characterize the relationship between endogenous 15d-PGJ 2 , infarct size, and biochemical markers.
15d-PGJ 2 is highly effective in reducing infarct volume when administered before a 50-minute MCA occlusion but loses its activity when administered after occlusion. Its window of effectiveness extends to 2 hours, but not 3 hours, when administered after a shorter (30 minutes) and therefore a milder ischemic insult. These results suggest that 15d-PGJ 2 acts on early pathophysiological events after ischemic injury.
It has been proposed that acute cerebral injury immediately after transient focal ischemia is attributed to energy failure and excitotoxicity that results in neuronal necrosis. 22 Acute ischemic injury also results in mitochondrial damage, which may lead to apoptosis. The extent of neuronal necrosis and apoptosis is influenced by the duration of MCA occlusion. A severe insult after a prolonged MCA occlusion causes predominantly neuronal necrosis, whereas a mild insult such as a 30-minute MCA occlusion incurs predominantly apoptosis. 23, 24 Our results show that 15d-PGJ 2 is capable of suppressing neuronal necrosis and apoptosis, thereby restricting the infarct development after a 50-minute or 30-minute MCA occlusion, albeit with a different window of effectiveness. Evidence supporting the action of 15d-PGJ 2 includes: (1) pretreatment of rat or human neurons with 15d-PGJ 2 prevented H 2 O 2 -induced cytotoxicity as detected by LDH leakage and reduction in MTT staining; (2) 15d-PGJ 2 prevented H 2 O 2 -induced neuronal apoptosis; and (3) administration of 15d-PGJ 2 intraventricularly abrogated caspase 3 activation in the ischemic cortex. Because necrosis develops rapidly after a severe ischemic injury, 15d-PGJ 2 is ineffective in controlling infarct size unless it is administered before I/R injury. By contrast, neuronal apoptosis induced by shorter ischemia takes place not as rapidly and therefore is responsive to 15d-PGJ 2 inhibition even after tissue damage has occurred.
Several pieces of evidence support the requirement of PPAR␥ activation for the protective action of 15d-PGJ 2 . First, the effect of 15d-PGJ 2 on reducing infarct volume in vivo was abrogated by a PPAR␥ inhibitor, GW9662. Second, the effect of 15d-PGJ 2 on protecting neuronal cytotoxicity and apoptosis was abrogated by another PPAR␥ inhibitor, BADGE. Third, known PPAR␥ ligands such as rosiglitazone inhibited I/R-induced brain infarction in vivo and H 2 O 2 -induced neuronal apoptosis and cytotoxicity in vitro. Activation of PPAR␥ has been shown to upregulate HO-1 expression 25, 26 and suppress the expression of an array of genes by blocking the transcriptional activity of transactivators such as NF-B. 12, 13 Our data confirm that 15d-PGJ 2 upregulates HO-1 expression, inhibits NF-B activation, and suppresses COX-2 expression in ischemic cortex and cultured neurons by a PPAR␥-dependent pathway. HO-1 possesses tissue protective properties, whereas NF-B mediated genes, such as COX-2, 13, 27 which aggravates tissue damage by producing proinflammatory prostanoids and reactive oxygen species. Upregulation of the protective HO-1 coupled with suppression of COX-2 and other NF-Bdependent genes via PPAR␥ activation represents a major mechanism by which 15d-PGJ 2 and rosiglitazone protect against I/R-induced neuronal necrosis and apoptosis and thereby limit the expansion of the infarct size.
We observed that 15d-PGJ 2 and rosiglitazone exhibit a concentration-dependent paradoxical effect on cytotoxicity. 15d-PGJ 2 induces LDH release at Ն5 mol/L but protects neurons from necrosis and apoptosis at Յ1 mol/L. This observation may explain the conflicting data reported in the literature. 15d-PGJ 2 was reported to induce apoptosis of several cell types including neurons 28 -32 and protect cerebellar granular cells from apoptosis. 33, 34 A detailed review of those reports reveals that the paradoxical effects of 15d-PGJ 2 may be caused by use of different 15d-PGJ 2 concentrations. Studies using 15d-PGJ 2 Ն10 mol/L reported a pro-apoptotic effect, whereas those using concentrations Յ1 mol/L were anti-apoptotic. The reason for this paradoxical action is unclear. Because rosiglitazone has a similar concentrationdependent paradoxical effect, it is tempting to speculate that PPAR␥ is involved. Further studies are needed to resolve this puzzle.
Our results reveal that PPAR␥ expression in rat brain tissues is increased by I/R and further enhanced by 15d-PGJ 2 and rosiglitazone. These results are consistent with an autoregulation of PPAR␥ by its ligands. It is unclear how 15d-PGJ 2 upregulates PPAR␥. 15d-PGJ 2 may enhance PPAR␥ at the transcriptional level or, alternatively, at the level of protein stability. Because PPAR␥ upregulation by 15d-PGJ 2 in BE(2)-C cells was blocked by BADGE, it is reasonable to conclude that ligand-induced PPAR␥ upregulation requires PPAR␥ activation, which creates a positive feedback loop for tissue protection.
Thiazolidinediones (TZD) have been shown to protect brain from I/R injury [35] [36] [37] and reduce myocardial infarction. 38 Pioglitazone and troglitazone administered intraperitoneally reduced infarct volume and improve neurological function accompanied by suppression of COX-2 and IL-1␤ in the rat stroke model. 35 Oral administration of pioglitazone for 4 days improved blood flow and reduced infarct volume in the rat model. 36 Our results show that intraventricular administration of rosiglitazone 2 hours after ischemia was effective in controlling infarct size. However, the effect was abated when administered after 3 hours. Thus, TZD drugs that are now commonly used clinically for treating diabetes may be useful in preventing I/R-induced tissue injury in humans. Although TZD alone has a narrow therapeutic window, its combination with PGI 2 analogs may prolong the therapeutic window and achieve a synergistic effect as PGI 2 protects against tissue damage by different mechanisms. 39, 40 
